Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Mark Diamond, CEO and managing director of Antisense Therapeutics (ASX:ANP).

One of the oldest ASX-listed biotechs, Antisense is focused on novel gene targeting therapies for rare diseases.

The company’s key focus is Duchenne Muscular Dystrophy (DMD), a genetic degenerative muscular condition that affects only boys.

Another is acromegaly, the enlargement of hands face and feet usually caused by a non-cancerous tumour.

So tune in to hear the pair discuss the company’s novel gene therapies, positive trial results and commercialisation ambitions.


On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!